12:00 AM
 | 
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Glufast mitiglinide: Phase III data

In a double-blind, U.S. Phase III trial (EX-1510-CT-003) in 350 patients, twice-daily oral mitiglinide plus metformin met the primary endpoint of a significant reduction in HbA1c from baseline vs. metformin plus placebo. The combination was well tolerated. Patients in the mitiglinide arm initially received...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >